Erythema multiforme
☆ Na nsonaazụ Stiftung Warentest nke 2022 sitere na Germany, afọ ojuju ndị ahịa na ModelDerm dị ntakịrị ntakịrị karịa na nyocha telemedicine akwụ ụgwọ.
Erythema multiforme minor ― Rụba ama na etiti ọnya ahụ nwere ike ịcha.
A pụkwara iwere urticaria dị ka nchọpụta dị iche.
relevance score : -100.0%
ReferencesErythema multiforme (EM) bụ ọnọdụ ebe ntụpọ dị iche iche na-apụta n'akpụkpọ ahụ na akpụkpọ anụ mucous n'ihi mmeghachi omume mgbochi. Ọ bụ ezie na ọrịa nje na-akpatakarị, karịsịa nje virus herpes simplex (HSV), ma ọ bụ ọgwụ ụfọdụ, a ka amabeghị ihe kpatara ya n'ọtụtụ ọnọdụ. Ịgwọ nnukwu EM na-elekwasị anya na ibelata mgbaàmà site na iji ude nwere steroid ma ọ bụ antihistamines. Ijikwa EM ugboro ugboro na-akacha arụ ọrụ mgbe ahaziri onye ọrịa ọ bụla. Ụzọ mbụ na-agụnye ma ọgwụgwọ ọnụ na nke elu. Ndị a gụnyere corticosteroids na mgbochi nje virus (antiviral). Ọgwụgwọ ndị dị n'elu gụnyere ude steroid siri ike yana ngwọta maka akpụkpọ ahụ mucous emetụtara. Maka ndị ọrịa na-anabataghị ọgwụ nje, nhọrọ nke abụọ na-agụnye ọgwụ na-egbochi mgbochi ọrịa, ọgwụ nje, anthelmintics, na mgbochi malaria (antimalarial).
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
Erythema multiforme (EM) is an immune-mediated condition that classically presents with discrete targetoid lesions and can involve both mucosal and cutaneous sites. While EM is typically preceded by viral infections, most notably herpes simplex virus (HSV), and certain medications, a large portion of cases are due to an unidentifiable cause. Treatment for acute EM is focused on relieving symptoms with topical steroids or antihistamines. Treatment for recurrent EM is most successful when tailored to individual patients. First line treatment for recurrent EM includes both systemic and topical therapies. Systemic therapies include corticosteroid therapy and antiviral prophylaxis. Topical therapies include high-potency corticosteroids, and antiseptic or anesthetic solutions for mucosal involvement. Second-line therapies for patients who do not respond to antiviral medications include immunosuppressive agents, antibiotics, anthelmintics, and antimalarials
N'ọtụtụ oge, erythema multiforme dị nro na-apụ n'onwe ya n'ime izu 2 ruo 4. Ọrịa Stevens‑Johnson syndrome, ọnọdụ siri ike na-emetụta mucous membranes, nwere ike ịdịru ruo izu isii. A naghị akwadokarị steroids maka obere ọnọdụ. Ma a ga-eji steroids mee ihe maka nnukwu erythema multiforme bụ ihe a na-ejighị n'aka ebe ọ bụ na ọ dịghị nchọpụta doro anya sitere na nchọpụta a na-enweghị usoro na-egosi nke ụmụaka ga-erite uru na ọgwụgwọ a.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
In most cases, mild erythema multiforme is self-limited and resolves in 2 to 4 weeks. Stevens-Johnson syndrome is a serious disease that involves the mucous membranes and lasts up to 6 weeks. There is no indication for using steroids for the mild form. Use of steroids for erythema multiforme major is debatable because no randomized studies clearly indicate which children will benefit from this treatment.
Anyị na-egosi ikpe nke ọnụ erythema multiforme (EM) kpatara TMP/SMX, na-egosi oral lesions na lip ulcerations na-enweghị skin lesions. Nke a na-egosi mkpa ọ dị ịmata ọdịiche dị na ya na ọrịa ọnya afọ ndị ọzọ. Onye ọrịa ahụ nwetara ọgwụgwọ symptomatic na tablet prednisolone, na-eduga na mmelite mgbe ọ kwụsịrị ọgwụgwọ TMP/SMX.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
We report a case of oral erythema multiforme (EM) secondary to TMP/SMX that presented with oral and lip ulcerations typical of EM without any skin lesions and highlights the importance of distinguishing them from other ulcerative disorders involving oral cavity. The patient was treated symptomatically and given tablet prednisolone. The condition improved with stoppage of TMP/SMX therapy.
Erythema multiforme bụ mmeghachi omume metụtara akpụkpọ ahụ na mgbe ụfọdụ mucosa, nke usoro ahụ ji alụso ọrịa ọgụ na‑ebute. Na‑emekarị, ọ na‑egosipụta dị ka ọnya ezubere iche, nke nwere ike ịpụta dịpụrụ adịpụ, na‑emegharị ma ọ bụ na‑adịgide. Ọnya ndị a na‑emetụtakarị nsọtụ, ọkachasị elu ha. Isi ihe na‑akpata ya gụnyere ọrịa dịka nje virus herpes simplex na Mycoplasma pneumoniae, yana ọgwụ ụfọdụ, ọgwụ mgbochi ọrịa, na ọrịa autoimmune. Ịmata ọdịiche erythema multiforme sitere na urticaria na‑adabere na ogologo oge ọnya; erythema multiforme ọnya na‑adịgide ma ọ dịkarịa ala ụbọchị asaa, ebe ọnya urticarial na‑apụkarị n’ime otu ụbọchị. Agbanyeghị, ọ dị mkpa ịmata ọdịiche erythema multiforme na Stevens‑Johnson syndrome, nke na‑egosipụtakarị erythematous ma ọ bụ purpuric macules nwere ọnya. Ijikwa erythema multiforme na‑agụnye enyemaka mgbaàmà na steroids ma ọ bụ ọgwụ antihistamines ma na‑agwa ihe kpatara ya. Maka okwu ugboro ugboro metụtara nje virus herpes simplex, a na‑tụ aro ọgwụgwọ prophylactic antiviral. Ntinye aka siri ike nke mucosal nwere ike ime ka a nabata ụlọ ọgwụ maka mmiri intravenous na nnọchi electrolyte.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Erythema multiforme is a reaction involving the skin and sometimes the mucosa, triggered by the immune system. Typically, it manifests as target-like lesions, which may appear isolated, recur, or persist. These lesions usually symmetrically affect the extremities, particularly their outer surfaces. The main causes include infections like herpes simplex virus and Mycoplasma pneumoniae, as well as certain medications, immunizations, and autoimmune diseases. Distinguishing erythema multiforme from urticaria relies on the duration of lesions; erythema multiforme lesions remain fixed for at least seven days, while urticarial lesions often vanish within a day. Although similar, it's crucial to differentiate erythema multiforme from the more severe Stevens-Johnson syndrome, which typically presents widespread erythematous or purpuric macules with blisters. Managing erythema multiforme involves symptomatic relief with topical steroids or antihistamines and addressing the underlying cause. For recurrent cases associated with herpes simplex virus, prophylactic antiviral therapy is recommended. Severe mucosal involvement may necessitate hospitalization for intravenous fluids and electrolyte replacement.
Ọnọdụ ahụ na-adịgasị iche site na mild rash, nke nwere oke onwe ya gaa n'ụdị siri ike, nke na-eyi ndụ egwu nke a maara dị ka erythema multiforme major nke na-agụnyekwa mucous membranes. Mwakpo nke mucous membranes ma ọ bụ ọnụnọ nke bullae bụ ihe ịrịba ama dị mkpa nke ịdị njọ.
- Erythema multiforme minor: target lesions or raised, edematous papules distributed acrally
Ụdị dị nro na-ebutekarị mild rash (ma itching nwere ike ịdị oke njọ), blotches pink-acha ọbara ọbara, nke a haziri nke ọma ma malite na nsọtụ. Mkpebi nke rash n'ime ụbọchị 7-10 bụ ụkpụrụ n'ụdị ọrịa a.
- Erythema multiforme major: target lesions or raised, edematous papules distributed acrally with involvement of one or more mucous membranes. Epidermal detachment involves less than 10 % of the total body surface area.
○ Ọgwụgwọ ― OTC Drugs
Ọ bụrụ na ọ na-esonyere ya na fever, a na-atụ aro ka ị gaa n'ụlọ ọgwụ ozugbo enwere ike.
Ekwesịrị ịkwụsị ọgwụ ndị a na-enyo enyo. (dịka ọmụmaatụ, antibiotics, nonsteroidal anti‑inflammatory drugs)
Ọgwụ antihistamines dị ka cetirizine na loratadine maka itching.
#Cetirizine [Zytec]
#LevoCetirizine [Xyzal]
#Loratadine [Claritin]